.

Board of Directors

Alfred D. Kingsley

Chairman of the Board

Alfred D. Kingsley joined the Board of Directors and became Chairman of the Board in 2009. Mr. Kingsley has been general partner of Greenway Partners, L.P., a private investment firm, and President of Greenbelt Corp., a business consulting firm, since 1993. Greenbelt Corp. served as our financial advisor from 1998 until June 30, 2009. Mr. Kingsley was Senior Vice-President of Icahn and Company and its affiliated entities for more than 25 years.

Mr. Kingsley holds a BS degree in economics from the Wharton School of the University of Pennsylvania, and a J.D. degree and LLM in taxation from New York University Law School.

William Annett

Chief Executive Officer

William Annett joined OncoCyte as Chief Executive Officer in June 2015. Mr. Annett’s diagnostics industry experience includes his service as CEO of BioFX Laboratories, Inc., which created innovative products in the in vitro diagnostics field and was successfully sold to a large life sciences company. He founded and led Corra Life Sciences, a prenatal diagnostics company, which worked with a consortium of universities to develop blood tests for the major diseases of pregnancy. Early in his career, Mr. Annett also founded a consumer products company, which he led for six years as CEO. During his tenure, the company became publicly traded on NASDAQ and was then acquired.

At Genentech, Mr. Annett led the Commercial Strategy group and managed large operational projects with several hundred team members. He also directed the Project Finance function for R&D, which supported all development pipeline products with more than 200 clinical trials. Most recently, Mr. Annett was a Managing Director at Accenture where he founded, built, and headed Accenture’s West Coast Life Sciences practice with sales, marketing, and delivery responsibilities for the entire territory. His clients included most of the major biotech and pharmaceutical companies in the western United States.

Mr. Annett holds an MBA from the Harvard Business School.

Andy Arno

Andy Arno was appointed as a member of the Board of Directors in June 2015. He is currently Vice Chairman of “The Special Equities Group” at Chardan Capital Markets, LLC, a privately held investment banking firm. He was previously Managing Director of Emerging Growth Equities, an investment bank, and Vice President of Sabr, Inc., as well as President of LOMUSA Limited, an investment banking firm. From 2009 to 2012, Andy served as Vice Chairman and Chief Marketing Officer of Unterberg Capital, LLC, an investment advisory firm that he co-founded. He also served as Vice Chairman and Head of Equity Capital Markets of Merriman Capital LLC, an investment banking firm, and served on the board of its parent company, Merriman Holdings, Inc. Mr. Arno currently serves on the Boards of Asterias Biotherapeutics and Smith Micro Software, Inc.

He is a graduate of George Washington University.

Andrew J. Last

Andrew J. Last joined the Board of Directors during December 2015. Mr. Last has been Executive Vice President and Chief Operating Officer of Affymetrix since 2010. Before joining Affymetrix, Mr. Last served as Vice President, Global and Strategic Marketing of BD Biosciences and as General Manager of Pharmingen from 2004 to 2010. From 2002 to 2004, Mr. Last held management positions at Applied Biosystems, Inc., including as Vice President and General Manager from 2003-2004 and Vice President of Marking 2002-2003 Earlier in his career, he served in a variety of management positions at other companies, including Incyte Genomics and Monsanto.

Mr. Last holds Ph. D. and MS degrees with specialization in Agrochemical Chemicals and Bio-Aeronautics, respectively, from Cranfield University, and a BS degree in Biological Sciences from the University of Leicester in the United Kingdom.

Adi Mohanty

Adi Mohanty joined the Board of Directors in April 2015. Mr. Mohanty currently has served as BioTime’s, Chief Operating Officer since December 2014 and Co-Chief Executive Officer since October 2015. He was formerly with Shire plc, a biotechnology company focused on research, development and commercialization of novel biological products for rare diseases, where he served in a number of executive positions, including as President/Head Regenerative Medicine from 2013 to 2014, as Senior Vice President, Business and Technical Operations from 2012 to 2013, and as Global Franchise Head MPS from 2010 to 2012. Mr. Mohanty served as Vice President at Transkaryotic Therapies from 2002 to 2005 when it was acquired by Shire. Before joining Transkaryotic Therapies, Mr. Mohanty held a number of management positions in the Bioscience Division of Baxter Healthcare Corporation.

Mr. Mohanty received an MBA degree from Saint Mary’s College and has an MS and BS in Chemical Engineering.

Cavan Redmond

Cavan Redmond joined the Board of Directors in September of 2015. Mr. Redmond is a seasoned healthcare strategist, who has held a number of global leadership positions. He currently is a partner at Zarsy, LLC. His global leadership roles include: CEO of WebMD Health Corp., where he oversaw cost rationalizations and streamlined operations to position the company for growth; Senior Vice President and Group President, Pfizer Diversified Businesses. The Diversified Business included Animal Health, Consumer Healthcare, Capsugel and Nutrition. While at Pfizer he also became the head of Corporate Strategy. While at Wyeth he was the first EVP and General Manager Wyeth Biopharma and President of Wyeth Consumer Healthcare. He is currently a member of the Board of Directors for the Arthritis Foundation, where he has served since 2014.

Mr. Redmond holds a MAS degree from Johns Hopkins University and a BA from the University of Maryland at College Park. He was a 2012 recipient of The Johns Hopkins University Distinguished Alumnus Award.

Don Bailey

Don Bailey joined OncoCyte’s Board of Directors in August 2016. Since February 2016 Mr. Bailey has served as the Chairman of the Board of Asterias Therapeutics (AST).  Previously, Mr. Bailey was President and Chief Executive Officer of Questcor Pharmaceuticals, Inc. from November 2007 until Questcor was acquired by Mallinckrodt in August 2014, and he also serves on Mallinckrodt’s Board of Directors.  Mr. Bailey was the non-executive Chairman of the Board of Directors of STAAR Surgical Company between 2005 and 2014. STAAR Surgical Company is a leader in the development, manufacture, and marketing of minimally invasive ophthalmic products.  Mr. Bailey served as Chief Executive Officer of Comarco, Inc. from 1991 until 2000, and became its Chairman of the Board from 1998 until 2007. 

Mr. Bailey holds a B.S. degree in mechanical engineering from the Drexel Institute of Technology, an M.S. degree in operations research from the University of Southern California, and an M.B.A. from Pepperdine University.